Selective non-steroidal aromatase inhibitor. It has anti-tumor activity against estrogen-dependent breast tumors in postmenopausal women. Reduces the content of circulating estradiol. Does not possess gestagenic, androgenic and estrogenic activity, does not affect the secretion of endogenous GCS and ISS.
Packaging video review Anastrozole 1 mg Teva
Early hormone-positive breast cancer in postmenopausal women (adjuvant therapy).
Common breast cancer in postmenopausal women.
Early hormone-positive breast cancer in postmenopausal women after tamoxifen therapy for 2-3 years (adjuvant therapy).